Le Méridien Vaccine (06660) announced that on March 24, 2024, the group submitted a novel process with high cost efficiency 2...
Zhitong Finance App News, Le Meridien Vaccine (06660) issued an announcement. The Group submitted a pre-application for clinical trials of the novel high-cost human diploid rabies vaccine on March 24, 2024. Currently, there are no effective treatments for rabies clinically, so post-exposure prophylaxis is essential. The main preventive measures are human rabies vaccination and passive immunization. The human diploid rabies vaccine has natural safety advantages and a broad market space.
The high-cost human diploid rabies vaccine developed by the Group was the first to break through the traditional technical bottleneck of low virus titer and low yield. Compared with similar products already marketed in China, product quality and safety have been significantly improved, and large-scale industrialized production capacity has been achieved.
The Group has completed the construction of a new process and a high-cost human diploid rabies vaccine workshop with production capacity that meets international standards, and is undergoing equipment commissioning and verification work. As the second largest rabies vaccine supplier in the world, the Group is leading the in-depth technological iterative upgrading of the global rabies vaccine. After the launch of the iterative rabies vaccine series, it will provide the market with better quality and safer rabies vaccine products to achieve new productivity in the industry.